X4 Pharmaceuticals (NASDAQ:XFOR) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

X4 Pharmaceuticals (NASDAQ:XFOR) announced its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04, FiscalAI reports. The company had revenue of $2.71 million during the quarter, compared to analysts’ expectations of $3.20 million. X4 Pharmaceuticals had a negative return on equity of 115.27% and a negative net margin of 225.55%.

X4 Pharmaceuticals Stock Performance

Shares of NASDAQ XFOR traded up $0.17 during mid-day trading on Wednesday, reaching $4.37. 516,794 shares of the company were exchanged, compared to its average volume of 453,693. The company’s 50-day simple moving average is $3.99 and its 200-day simple moving average is $3.80. The company has a quick ratio of 9.98, a current ratio of 10.16 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $396.96 million, a P/E ratio of -1.00 and a beta of 0.31. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83.

Institutional Trading of X4 Pharmaceuticals

A number of hedge funds have recently modified their holdings of XFOR. Bain Capital Life Sciences Investors LLC lifted its stake in shares of X4 Pharmaceuticals by 227.0% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 7,967,454 shares of the company’s stock worth $31,870,000 after buying an additional 5,530,866 shares during the last quarter. Kalehua Capital Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $14,891,000. Braidwell LP acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $13,476,000. Nantahala Capital Management LLC acquired a new stake in shares of X4 Pharmaceuticals during the 3rd quarter worth about $7,621,000. Finally, Siren L.L.C. acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $6,000,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Analyst Upgrades and Downgrades

XFOR has been the subject of several analyst reports. Guggenheim assumed coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective for the company. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings upgraded shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, X4 Pharmaceuticals has an average rating of “Hold” and an average price target of $8.50.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.